Canopy Growth (CGC) Income from Continuing Operations (2019 - 2026)
Canopy Growth (CGC) posted Income from Continuing Operations of 77577262.44 for Q4 2025, down 2044.68% sequentially from 3617189.04 in Q3 2025, and down 10.49% YoY from 86667892.64 in Q4 2024.
Canopy Growth (CGC) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Canopy Growth has reported Income from Continuing Operations for 7 years, with the latest figure at 77577262.44 in Q4 2025.
- Quarterly Income from Continuing Operations fell 10.49% year-over-year to 77577262.44 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 183783827.17 (up 46.47% YoY) and the FY2026 annual result came in at 191744636.7, down 173.54% from the prior year.
- Income from Continuing Operations retreated to 77577262.44 in Q4 2025 per CGC's latest filing, from 3617189.04 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 317238982.72 in Q2 2021 and troughed at 1640644562.36 in Q2 2022.
- A 5-year average of 147661271.75 and a median of 82263253.69 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2022: Income from Continuing Operations surged 442.79% in 2021, then sank 1061.13% in 2022.
- Over 5 years, Income from Continuing Operations stood at 91627144.08 in 2021, then slumped by 82.39% to 167116641.72 in 2022, then climbed by 3.68% to 160968319.01 in 2023, then soared by 56.38% to 70212631.25 in 2024, then declined by 10.49% to 77577262.44 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 77577262.44, 3617189.04, and 32376744.43 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Canopy Growth | 431.13 Mn | 184.12 Mn | 16.08 Mn | -10.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.54 Mn |
| Dec 31, 2025 | -77.58 Mn |
| Sep 30, 2025 | -3.62 Mn |
| Jun 30, 2025 | -32.38 Mn |
| Dec 31, 2024 | -70.21 Mn |
| Sep 30, 2024 | -82.26 Mn |
| Jun 30, 2024 | -78.91 Mn |
| Mar 31, 2024 | -111.94 Mn |
| Dec 31, 2023 | -160.97 Mn |
| Sep 30, 2023 | -104.09 Mn |
| Jun 30, 2023 | -7.87 Mn |
| Mar 31, 2023 | 165.78 Mn |
| Dec 31, 2022 | -167.12 Mn |
| Sep 30, 2022 | -150.64 Mn |
| Jun 30, 2022 | -1.64 Bn |
| Mar 31, 2022 | -408.19 Mn |
| Dec 31, 2021 | -91.63 Mn |
| Sep 30, 2021 | -12.97 Mn |
| Jun 30, 2021 | 317.24 Mn |
| Mar 31, 2021 | -87.57 Mn |